Celeris Therapeutics

United States
New Lisbon, Wisconsin, United States, 94025

Company profile

Celeris Therapeutics company profile

Celeris Therapeutics is an AI-first drug discovery company that develops proximity-inducing compounds (PICs), focusing on PIC degraders for diseases with high unmet medical needs, such as Parkinson's and various types of cancers. Celeris Therapeutics has developed the Celeris One platform to streamline the development of degraders and, most importantly, rationalize their design. Celeris One leverages structure-based geometric deep learning to prioritize specific E3 ligases, design linkers, and select the most active compounds for synthesis. An in-house automated lab quickly generates experimental data for additional optimization cycles. Celeris Therapeutics collaborates with pharma and biotech companies to jointly discover and develop small-molecule degrader medicines for all therapeutic areas. It is also developing an in-house drug pipeline. Celeris Therapeutics has offices in Menlo Park, CA, and Graz, Austria.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2021-01-01, Month

Headquarters

Postal code
94025
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding rounds
5
Total equity funding
$14.4M
Last funding
Series Unknown / $9.8M / 2022-10-19
Last equity funding
Series Unknown / $9.8M
Investors
6
Lead investors
5
Founders
1
Articles
4

Founders and investors

Founders

Christopher Trummer

Lead investors

APEX VenturesEuropean Innovation Councili&i PragueLongevitytech.fundPace Ventures

Investors

APEX VenturesEuropean Innovation CouncilLongevitytech.fundPace VenturesR42 Group